Company intelligence / Profile preview
Reyon Pharmaceutical
Seoul, South Koreareyonpharm.co.kr ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Reyon Pharmaceutical has a diversified pipeline spanning generic medicines/APIs to advanced biotherapeutics. Its lead gene therapy program NG101 for wAMD entered Phase 1/2a trials in Canada in 2023 with plans to expand into the US. The company also co-develops an iPSC-derived NK cell immunotherapy TB-100 with Therabest targeting solid tumors—preclinical as of early 2025—with domestic clinical trials planned.
- Therapeutic areas
- NephrologyOphthalmologyOncologyNeurologyInfectious Diseases
- Modalities
- Gene therapyantibody therapycell therapy (including iPSC-derived NK cells)small molecules (generic drugs and APIs)mRNA therapiessynthetic peptides
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Neuracle Genetics/Neuracle Science Co., Ltd. – co-development of NG101 AAV gene therapyTherabest – joint development of TB‑100 iPSC-NK cell immunotherapyFINZELBERG & G&P – strategic cooperation on specialty drug development/tissue regeneration products
Beyond the preview
Go deeper on Reyon Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Reyon Pharmaceutical.